These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
285 related articles for article (PubMed ID: 27684826)
1. In vivo expansion and activation of γδ T cells as immunotherapy for refractory neuroblastoma: A phase 1 study. Pressey JG; Adams J; Harkins L; Kelly D; You Z; Lamb LS Medicine (Baltimore); 2016 Sep; 95(39):e4909. PubMed ID: 27684826 [TBL] [Abstract][Full Text] [Related]
2. Zoledronate sensitizes neuroblastoma-derived tumor-initiating cells to cytolysis mediated by human γδ T cells. Nishio N; Fujita M; Tanaka Y; Maki H; Zhang R; Hirosawa T; Demachi-Okamura A; Uemura Y; Taguchi O; Takahashi Y; Kojima S; Kuzushima K J Immunother; 2012 Oct; 35(8):598-606. PubMed ID: 22996365 [TBL] [Abstract][Full Text] [Related]
3. Induction of gamma delta T cells using zoledronate plus interleukin-2 in patients with metastatic cancer. Nagamine I; Yamaguchi Y; Ohara M; Ikeda T; Okada M Hiroshima J Med Sci; 2009 Mar; 58(1):37-44. PubMed ID: 19400555 [TBL] [Abstract][Full Text] [Related]
4. Mechanisms of the antitumor activity of human Vγ9Vδ2 T cells in combination with zoledronic acid in a preclinical model of neuroblastoma. Di Carlo E; Bocca P; Emionite L; Cilli M; Cipollone G; Morandi F; Raffaghello L; Pistoia V; Prigione I Mol Ther; 2013 May; 21(5):1034-43. PubMed ID: 23481325 [TBL] [Abstract][Full Text] [Related]
5. Zoledronic acid and interleukin-2 treatment improves immunocompetence in HIV-infected persons by activating Vgamma9Vdelta2 T cells. Poccia F; Gioia C; Martini F; Sacchi A; Piacentini P; Tempestilli M; Agrati C; Amendola A; Abdeddaim A; Vlassi C; Malkovsky M; D'Offizi G AIDS; 2009 Mar; 23(5):555-65. PubMed ID: 19238075 [TBL] [Abstract][Full Text] [Related]
6. Zoledronate-activated Vγ9γδ T cell-based immunotherapy is feasible and restores the impairment of γδ T cells in patients with solid tumors. Noguchi A; Kaneko T; Kamigaki T; Fujimoto K; Ozawa M; Saito M; Ariyoshi N; Goto S Cytotherapy; 2011 Jan; 13(1):92-7. PubMed ID: 20831354 [TBL] [Abstract][Full Text] [Related]
7. Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Wilhelm M; Kunzmann V; Eckstein S; Reimer P; Weissinger F; Ruediger T; Tony HP Blood; 2003 Jul; 102(1):200-6. PubMed ID: 12623838 [TBL] [Abstract][Full Text] [Related]
8. Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Dieli F; Vermijlen D; Fulfaro F; Caccamo N; Meraviglia S; Cicero G; Roberts A; Buccheri S; D'Asaro M; Gebbia N; Salerno A; Eberl M; Hayday AC Cancer Res; 2007 Aug; 67(15):7450-7. PubMed ID: 17671215 [TBL] [Abstract][Full Text] [Related]
9. Hepatocellular carcinoma cell sensitivity to Vγ9Vδ2 T lymphocyte-mediated killing is increased by zoledronate. Sugai S; Yoshikawa T; Iwama T; Tsuchiya N; Ueda N; Fujinami N; Shimomura M; Zhang R; Kaneko S; Uemura Y; Nakatsura T Int J Oncol; 2016 May; 48(5):1794-804. PubMed ID: 26936487 [TBL] [Abstract][Full Text] [Related]
10. Effect of IL-18 on expansion of gammadelta T cells stimulated by zoledronate and IL-2. Li W; Kubo S; Okuda A; Yamamoto H; Ueda H; Tanaka T; Nakamura H; Yamanishi H; Terada N; Okamura H J Immunother; 2010 Apr; 33(3):287-96. PubMed ID: 20445349 [TBL] [Abstract][Full Text] [Related]
11. Impaired function of gamma-delta lymphocytes in melanoma patients. Petrini I; Pacini S; Galimberti S; Taddei MR; Romanini A; Petrini M Eur J Clin Invest; 2011 Nov; 41(11):1186-94. PubMed ID: 22775565 [TBL] [Abstract][Full Text] [Related]
12. Adoptive immunotherapy for advanced non-small cell lung cancer using zoledronate-expanded γδTcells: a phase I clinical study. Sakamoto M; Nakajima J; Murakawa T; Fukami T; Yoshida Y; Murayama T; Takamoto S; Matsushita H; Kakimi K J Immunother; 2011 Mar; 34(2):202-11. PubMed ID: 21304399 [TBL] [Abstract][Full Text] [Related]
13. Expansion of human peripheral blood γδ T cells using zoledronate. Kondo M; Izumi T; Fujieda N; Kondo A; Morishita T; Matsushita H; Kakimi K J Vis Exp; 2011 Sep; (55):. PubMed ID: 21931292 [TBL] [Abstract][Full Text] [Related]
14. Progression of natural immunity during one-year treatment of residual disease in neuroblastoma patients with high doses of interleukin-2 after autologous bone marrow transplantation. Martí F; Pardo N; Peiró M; Bertran E; Amill B; García J; Cubells J; Rueda F Exp Hematol; 1995 Dec; 23(14):1445-52. PubMed ID: 8542930 [TBL] [Abstract][Full Text] [Related]
15. [Effect of zoledronate on the cytotoxicity of γδ T cells from PBMCs of osteosarcoma patients against osteosarcoma]. Li Z; Tang J; Sun L; Ye Z Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Jan; 29(1):6-9. PubMed ID: 23294710 [TBL] [Abstract][Full Text] [Related]
16. In vitro expansion of gamma delta T cells with anti-myeloma cell activity by Phosphostim and IL-2 in patients with multiple myeloma. Burjanadzé M; Condomines M; Reme T; Quittet P; Latry P; Lugagne C; Romagne F; Morel Y; Rossi JF; Klein B; Lu ZY Br J Haematol; 2007 Oct; 139(2):206-16. PubMed ID: 17897296 [TBL] [Abstract][Full Text] [Related]
17. [Amplification of γδ T cells in PBMCs of healthy donors and osteosarcoma patients stimulated by zoledronate]. Li ZX; Sun LL; Cheng RL; Sun ZW; Ye ZM Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2012 Aug; 28(8):822-4. PubMed ID: 22863589 [TBL] [Abstract][Full Text] [Related]
18. In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients. Meraviglia S; Eberl M; Vermijlen D; Todaro M; Buccheri S; Cicero G; La Mendola C; Guggino G; D'Asaro M; Orlando V; Scarpa F; Roberts A; Caccamo N; Stassi G; Dieli F; Hayday AC Clin Exp Immunol; 2010 Aug; 161(2):290-7. PubMed ID: 20491785 [TBL] [Abstract][Full Text] [Related]
19. Ex vivo characterization of γδ T-cell repertoire in patients after adoptive transfer of Vγ9Vδ2 T cells expressing the interleukin-2 receptor β-chain and the common γ-chain. Izumi T; Kondo M; Takahashi T; Fujieda N; Kondo A; Tamura N; Murakawa T; Nakajima J; Matsushita H; Kakimi K Cytotherapy; 2013 Apr; 15(4):481-91. PubMed ID: 23391461 [TBL] [Abstract][Full Text] [Related]
20. Essential requirements of zoledronate-induced cytokine and γδ T cell proliferative responses. Nussbaumer O; Gruenbacher G; Gander H; Komuczki J; Rahm A; Thurnher M J Immunol; 2013 Aug; 191(3):1346-55. PubMed ID: 23794630 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]